REG - GSK PLC - Director/PDMR Shareholding
15/02/2024 15:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240215:nRSO3367Da&default-theme=true
RNS Number : 3367D GSK PLC 15 February 2024
GSK plc (the 'Company')
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of
Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons Discharging
Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary
Shares and American Depositary Shares ('ADSs') made in 2021 under the
GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale
of Ordinary Shares and ADSs to meet tax liabilities. In accordance with the
shareholder approved 2017 Remuneration Policy and the DABP rules, the awards
comprised a mandatory bonus deferral only. The three-year restricted period
for the awards commenced on 10 February 2021 and ended on 12 February 2024.
Dividends accrued on the awards during the restricted period.
The awards were granted in 2021 as restricted awards over ADSs for US
participants and as nil-cost options over Ordinary Shares for all other
participants.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on 12
February 2024 were £16.264 and $41.07.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 52,435
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5180 24,682
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Hal Barron
b) Position/status Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The vesting of an award granted in 2021 under the Company's 2017 Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 27,796
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Hal Barron
b) Position/status Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADSs' to meet tax liabilities on the vesting of an award granted
in 2021 under the Company's 2017 Deferred Annual Bonus Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$41.0648 14,941
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 7,600
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5104 4,083
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 9,157
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5056 4,319
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 4,627
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5238 2,183
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 14,209
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5020 166
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 11,169
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5152 5,263
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 8,414
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4822 3,969
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 6,532
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4906 3,081
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 13,426
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.5186 6,327
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-12
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFSFIIELSEDERecent news on GSK
See all newsREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK announces additional EAGLE-1 results
AnnouncementREG - GSK PLC - Results from long-term data relating to Shingrix
Announcement